PCN52 Cost-Effectiveness Analysis of the Third-LINE Treatment of Regorafenib for Metastatic or Unresectable Gastrointestinal Stromal Tumors in China
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.144
https://www.valueinhealthjournal.com/article/S1098-3015(21)00361-2/fulltext
Title :
PCN52 Cost-Effectiveness Analysis of the Third-LINE Treatment of Regorafenib for Metastatic or Unresectable Gastrointestinal Stromal Tumors in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00361-2&doi=10.1016/j.jval.2021.04.144
First page :
Section Title :
Open access? :
No
Section Order :
10719